SPOTIFY
1.2.2021 23:03:12 CET | Business Wire | Press release
Today Spotify (NYSE: SPOT) launches its service in South Korea, giving Korean listeners access to over 60 million tracks and over 4 billion playlists from around the world. As the world’s most popular audio streaming subscription service, Spotify offers an effortlessly simple interface, an innovative technology framework, everyday new music discovery and algorithmic recommendations personalized to each listener’s music taste. This launch brings Spotify’s total number of markets to 93.
As the sixth-largest music market in the world*, South Korea is a critical next step in Spotify’s global expansion journey. Not only is South Korea among the most digitally inclusive markets in the world, but it is also widely recognized as a cultural and music epicenter, in part due to the global phenomena K-Pop. Since Spotify debuted its first K-Pop playlist in 2014, the share of K-Pop listening on the platform has increased by more than 2,000%. With this launch, Spotify plans to accelerate the growth of Korea’s entire music streaming ecosystem, benefitting creators, labels, distributors and fans.
“We always want to be where the listeners and artists are, and Korea is rich in both,” said Alex Norström, Chief Freemium Business Officer of Spotify. “This launch presents a massive opportunity for us to not only further our mission of bringing new and quality content to more audiences, but also help local Korean artists tap into Spotify’s 320 million listeners worldwide. We hope to create more opportunities for Korean artists across all genres to be discovered by listeners around the world.”
Spotify has uniquely tailored the music experience for each market. As a part of today’s launch, Spotify is introducing a range of new playlists made exclusively for South Korea. These playlists offer curated and the latest music from our team of Korean music experts, across some of the most popular genres. These include:
- TOP Playlists: Korean Music Hot Now , FRESH! New Music Korea , Hot Hits Korea , Korean Music Rising , Today's Drama OST Hot Now , K-Pop Daebak and more
- Genre Playlists : TrenChill K-R&B , TrenChill K-Hip Hop , K-HIP-HOP +82 , K-Are & Be , In The K-Indie , Korean City Pop , K-Rock Spirit , Folk & Acoustic Hot Now , Orchestra Korean Ballad and more
- Thematic Playlists : You Did Well , The End of the Day , So Cool Driving , Brain Rest 432Hz , Lullaby zZZ , Transcendental Game Play , Running K-Pop , GAYO Instrumentals , Spring Music , Into the Rain , Next Page of the Break-up , Kitchen Melodies and more
- ‘Starring’ playlists : This Is BTS , This Is BLACKPINK , This Is Stray Kids , This Is NCT , This Is TWICE , This is Taeyeon , This Is JAY Park , This Is CHUNG HA , This Is Loco and more
These new playlists will join Spotify’s K-Pop genre hub that encompasses a wide range of Korean music, including K-pop, Hip Hop, Indie, OST, R&B and more, as well as ‘RADAR Korea’, a playlist uncovering fresh K-music finds and a part of Spotify’s global emerging artist program. The hub is localized in over 72 countries, including Russia, India, Brazil and the UAE.
In Korea, new listeners can try out Spotify Premium 7 days-free on their mobile phone with no credit card information and a total of 3 months-free with credit card information, if subscribed before the end of June 2021. Listeners can engage with Spotify across a wide range of devices and app integrations including Instagram, Facebook, Samsung mobile and TV, LG TV, Microsoft Xbox, Bose and more.
The Spotify app is available to download for both Premium Individual and Duo plans. To enjoy music the way you want it, download the Spotify app today via the Android or iOS app store or by heading to www.spotify.com/kr-ko/ .
Click here for further imagery.
* According to IFPI (https://www.ifpi.org/wp-content/uploads/2020/07/Global_Music_Report-the_Industry_in_2019-en.pdf )
About Spotify Technology S.A.
Spotify transformed music listening forever when we launched in 2008. Our mission is to unlock the potential of human creativity by giving a million creative artists the opportunity to live off their art and billions of fans the opportunity to enjoy and be inspired by these creators.
Today, with over 60 million tracks and over 4 billion playlists, we are the world’s most popular audio streaming subscription service with a community of more than 320 million listeners across 93 markets.
We use our Investors and For the Record websites as well as other social media listed in the “Resources – Social Media” tab of our Investors website to disclose material company information. For more information, images, or to contact the press team, head over to https://newsroom.spotify.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom